BRIDGEBIO PHARMA INC (BBIO:NASDAQ)
$80.09 -2.05 (-2.4957%)
Analysed BRIDGEBIO PHARMA INC (BBIO:NASDAQ) News Sources
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?
10-07-2026
trefis.com
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
10-07-2026
yahoo.com
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10-07-2026
yahoo.com
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
13-07-2026
marketbeat.com
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
14-07-2026
yahoo.com
Yext, Mission Produce, and 3 More Stocks See Action From Activist Investors
17-07-2026
yahoo.com
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
22-07-2026
yahoo.com
FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug
23-07-2026
yahoo.com
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?
28-07-2026
yahoo.com
Alnylam plunges as earnings deliver ‘one-two punch’
30-07-2026
biopharmadive.com
What is the current price of BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The current price of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is $80.09.
BRIDGEBIO PHARMA INC (BBIO:NASDAQ) absolute price change since previous trading day?
The absolute price change of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) since the previous trading day is $-2.05.
BRIDGEBIO PHARMA INC (BBIO:NASDAQ) percentage price change since previous trading day?
The percentage price change of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) since the previous trading day is -2.4957%.
What is the most recent average sentiment score for BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The most recent average sentiment score for BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is 49 out of 100.
What is the most recent average sentiment for BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The most recent sentiment for BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is .
SEC-8K** Filing Available For BRIDGEBIO PHARMA INC (BBIO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.